IMA
$6.02
Pre-MarketAs of Mar 17, 8:00 PM UTC
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Recent News
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
ImageneBio, Inc. ( NASDAQ:IMA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.